Windtree Therapeutics, a Nasdaq-listed biotech firm, plans to purchase up to $700 million worth of BNB, following the cryptocurrency's recent all-time high. The company aims to enhance its balance sheet by investing in digital assets, having previously announced intentions to acquire $200 million in BNB. It will raise approximately $520 million through a $500 million equity credit line and a $20 million stock-purchase agreement, partnering with Kraken for asset custody. BNB, currently the fifth-largest digital currency with a market cap of $106.9 billion, hit a peak of $808 before experiencing a slight decline. Windtree's stock faces a 5% drop, despite a 162% rise over the past month, joining a trend where several publicly traded companies are diversifying into cryptocurrencies, not limited to Bitcoin. Other firms like Nano Labs are also pursuing substantial BNB investments, reflecting a growing interest in crypto treasuries among corporations.

Source đź”—